… Analysis by BMI category <30 kg/m 2 compared with ≥30 kg/m 2 was a pre-specified
subgroup analysis in DAPA-HF but we provide more granularity about the effect of dapagliflozin …

… clinical trial, DAPA-HF, which used the SGLT2 inhibitor dapagliflozin and included 4,744 …
worsening HF or death from cardiovascular causes was significantly lower in the dapagliflozin …

… Dapagliflozin is an SGLT-2 inhibitor used as an oral antidiabetic drug. The DAPA-HF study
showed that dapagliflozin significantly decreased hospitalization due to HF and cardiac …

… DAPA HF evaluated the efficacy and safety of the dapagliflozin in patients with HF and …
Patients with symptomatic HF due to reduced ejection fraction treated with dapagliflozin had …

… SOC rates multiplied by the DAPA-HF HR (eMethods 3 in … dapagliflozin arm. We modeled
an adverse event rate based on DAPA-HF; we assumed patients discontinued dapagliflozin …

… DAPA-CKD trial, we determined the effects of dapagliflozin … of the DAPA-CKD trial, we
demonstrated that dapagliflozin … The benefits of dapagliflozin on overall mortality were driven …

… We therefore studied the effects of the GLP-1 RA liraglutide (Lira) and the SGLT2i dapagliflozin
(Dapa) on cardiac structure and function in a novel cardiometabolic HFpEF mouse model…

… Patients were stratified by KCCQ-TSS tertiles; Cox models examined effects of dapagliflozin
on clinical outcomes. We evaluated the effects of dapagliflozin on KCCQ-TSS, Physical …

… effects of SGLT2 inhibition had not previously been studied in this population. Dapagliflozin
… In this post hoc analysis of the DAPA-CKD trial, we assessed the effects of dapagliflozin on …

… other key trials evaluating dapagliflozin: The DAPA-HF study [18] and the DAPA-CKD study
[… those of the DAPA-HF study and determine whether the impact of dapagliflozin on the rate of …